9,10-seco- Cyclopentanohydrophenanthrene Ring System (e.g., Vitamin D, Etc.) Doai Patents (Class 514/167)
-
Publication number: 20140206656Abstract: This disclosure provides products, including pharmaceutical compositions and dietary supplements, which are useful for anti-inflammatory support.Type: ApplicationFiled: January 29, 2014Publication date: July 24, 2014Applicant: Rock Creek Pharmaceuticals, Inc.Inventor: Jonnie R. Williams
-
Publication number: 20140206654Abstract: The present invention refers to the use of a compound of Formula (I?) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of hematological dyscrasias, including myelodysplastic syndromes (MDSs) and for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. In addition, it relates to the use of a compound of formula (I?) for the treatment and/or prophylaxis of cancer of an organ.Type: ApplicationFiled: August 12, 2013Publication date: July 24, 2014Applicant: Action Medicines, S.L.Inventors: Pedro Cuevas Sanchez, Guillermo Gimenez Gallego, Inigo Saenz De Tejada Morgan, Javier Angulo Frutos, Rosa Maria Lozano Puerto, Antonio Romero Garrido, Serafin Valverde Lopez
-
Publication number: 20140206655Abstract: Disclosed are (22E)-2-methylene-22-dehydro-1,24,25-trihydroxy-19-nor-vitamin D3 compounds, their biological activities, and various pharmaceutical uses for these compounds. Particularly disclosed are (22E)-(24R)-2-methylene-22-dehydro-1?,24,25-trihydroxy-19-nor-vitamin D3 and (22E)-(24S)-2-methylene-22-dehydro-1?,24,25-trihydroxy-19-nor-vitamin D3, their biological activities, and various pharmaceutical uses for these compounds.Type: ApplicationFiled: November 19, 2013Publication date: July 24, 2014Applicant: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Lori A. Plum, Rafal Barycki, Margaret Clagett-Dame
-
Publication number: 20140205648Abstract: The present invention relates to methods for in situ treatment of malignant cells from a cancer associated with bone. In one method, the treatment is for a primary cancer and entails positioning an implant containing and/or coated with at least one active agent for treating malignant cells directly in/on or indirectly among/near (e.g., by placing the implant in an area immediately proximal to) a site containing the malignant cells. In another method, the treatment includes positioning an implant containing and/or coated with at least one active agent for treating malignant cells directly in/on or indirectly among/near (e.g., by placing the implant in an area immediately proximal to) a surgical site from which malignant cells were previously removed/excised.Type: ApplicationFiled: April 3, 2014Publication date: July 24, 2014Applicant: DePuy Synthes Products, LLCInventor: Maria Maccecchini
-
Patent number: 8785422Abstract: Disclosed are 19-nor-vitamin D compounds, and specifically seco-A-2,19-dinor-1,25-dihydroxyvitamin D3 as well as pharmaceutical uses therefor. These compounds exhibit relatively high activity in vivo, specifically in intestinal tissues, but relatively low VDR binding activity, cell differentiation activity and gene transcription activity. There is thus potential for these compounds to have strong cell selectivity for use as therapeutic agents against some cancers, such as colon cancer or polyps, as well as hyperplastic intestinal disorders, such as Crohn's disease, ulcerative colitis and celiac disease. These compounds also have relatively high intestinal calcium transport activity evidencing potential in the treatment of bone diseases.Type: GrantFiled: March 14, 2013Date of Patent: July 22, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Margaret Clagett-Dame, Lori A. Plum, Agnieszka Glebocka
-
Patent number: 8785421Abstract: Hydroxylated derivatives of vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol) are effective for preventing or treating mastitis in animals. The hydroxylated derivatives of vitamins D3 or D2 are administered to the mammary gland of a female animal in an amount effective to inhibit or significantly reduce the growth of bacteria in the animal's mammary gland.Type: GrantFiled: March 30, 2012Date of Patent: July 22, 2014Assignee: The United States of America as represented by the Secretary of AgricultureInventors: John D. Lippolis, Timothy A. Reinhardt
-
Publication number: 20140200201Abstract: Provided herein are steroidal compounds that are androsta-5,7-dienes or a pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof which includes pharmaceutical compositions of the steroidal compounds as shown in Tables 1 and 2. Also provided is a method for producing hydroxylated metabolites of cholecalciferol or ergocalciferol via the P450scc (CYP11A1) or CYP27B1 enzyme systems where the hydroxylase has an activity to hydroxylate position C20 of a secosteroid or its 5,7-dieneal precursor and the hydroxylated metabolites so produced. In addition, a method for inhibiting proliferation of either a normally or abnormally proliferating cell by contacting the cell with any of the compounds described herein. A related method is provided of treating a condition associated with the proliferating cell such as a cancer, a skin disorder, a defect in cell differentiation, cosmetic, prophylaxsis, or healthy cell maintenance.Type: ApplicationFiled: February 28, 2013Publication date: July 17, 2014Inventors: Andrzej T. Slominski, Robert C. Tuckey, Blazej Zbytek, Michal A. Zmijewski, Minh Ngoc Nguyen, Zorica Janjetovic, Jianjun Chen, Wei Li, Duane D. Miller, Jordan K. Zjawiony, Arnold E. Postlethwaite, Trevor W. Sweatman
-
Patent number: 8771701Abstract: The present invention relates to a method of eliciting a cytotoxic T lymphocyte response to an antigen in an animal, the method comprising pulsing mannose receptor-bearing antigen presenting cells in vitro or ex vivo with a conjugate comprising an antigen and a carbohydrate polymer comprising mannose, wherein said carbohydrate polymer is a fully oxidized carbohydrate polymer comprising free aldehydes; and administering the pulsed antigen presenting cells to an animal.Type: GrantFiled: November 17, 2006Date of Patent: July 8, 2014Assignee: MacFarlane Burnet Institute for Medical Research and Public Health LtdInventors: Ian F. C. McKenzie, Vasso Apostolopoulos, Geoffrey A. Pietersz
-
Publication number: 20140186466Abstract: Disclosed are compositions of matter useful for the treatment of diabetes. In one embodiment a nutraceutical composition is administered to a patient in need, said composition comprising of one or more ingredients selected from a group consisting of: magnesium, chromium picolinate, alpha lipoic acid, Garcina indica, holy basil, Morodica charantica, cinnamon, Salacia reticulate, Salacia oblonga, Gymnema sylvestre, nopal cactus, fenu greek, vanadium, 1-carnitine, and vitamin D3.Type: ApplicationFiled: December 31, 2013Publication date: July 3, 2014Applicant: Creative Medical Health Inc.Inventor: Amit Patel
-
Publication number: 20140186471Abstract: The present invention relates to the a method of inhibiting bone resorption in a mammal in need thereof with an oral pharmaceutical composition comprising a cathepsin K inhibitor, or a pharmaceutically acceptable salt thereof, or a mixture thereof, according to a continuous schedule having a dosage interval of once weekly, biweekly, twice monthly or once monthly.Type: ApplicationFiled: March 5, 2014Publication date: July 3, 2014Inventors: Anastasia Daifotis, Selwyn Aubrey Stoch, Basil Avery Ince, Cameron Black
-
Use of 2-Methylene-19-Nor-(20S)-1alpha,25-Dihydroxyvitamin D3 to Treat Secondary Hyperparathyroidism
Publication number: 20140187522Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.Type: ApplicationFiled: March 7, 2014Publication date: July 3, 2014Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Hector F. DeLuca, Julia B. Zella, Lori A. Plum, Margaret Clagett-Dame, Wendy Bedale -
Publication number: 20140187520Abstract: The present invention relates to a stable pharmaceutical composition for intravenous administration comprising a Vitamin D receptor agonist, particularly paricalcitol, and a process of preparation thereof.Type: ApplicationFiled: December 10, 2013Publication date: July 3, 2014Applicant: PHARMATHEN S.A.Inventors: EFTHIMIOS KOUTRIS, EVANGELOS KARAVAS, IOANNA KOUTRI, MORFIS ABATZIS, VASILIKI SAMARA, ATHINA ILIOPOULOU
-
Publication number: 20140187521Abstract: Methods of treating patients with inflammatory bowel disease, intestinal fibrosis, or Crohn's disease involve administering a therapeutic amount of CARD-024 or related compound.Type: ApplicationFiled: December 19, 2013Publication date: July 3, 2014Inventors: Robert U. Simpson, Peter D.R. Higgins, Laura A. Johnson
-
Publication number: 20140186468Abstract: The present invention provides a unique combination of biomarkers that identify triple-negative breast cancer (TNBC) patient subpopulations. Such subpopulations will have differential responses to therapies, and thus treatments can be tailored to particular patients.Type: ApplicationFiled: December 6, 2013Publication date: July 3, 2014Inventors: Susana GONZALO, Adriana DUSSO, Xavier MATIAS-GUIU, Anna Novell ALVAREZ, Ignacio GONZALEZ-SUAREZ, David GROTSKY
-
Publication number: 20140186278Abstract: An anhydrous multiphase gel system consisting of an outer lipid matrix and an inner phase gelled by means of a polymer is described, which can be obtained by a) Melting the lipid phase with the formation of a liquid lipid phase, b) Mixing and homogenizing polymers or polymer blends capable of swelling with the formation of a polymer phase to be dispersed, c) Combining the polymer phase with the liquid lipid phase and homogenizing the phases, and d) Cold stirring the phase mixture until a solid gel-like mixed structure of the entire system is formed. The anhydrous multiphase gel system is particularly suitable for taking up difficulty soluble active substances in high concentration and for providing topical and transdermal applications. The described system is called an EDRS, “Entrapped Drug Reservoir System”.Type: ApplicationFiled: September 19, 2013Publication date: July 3, 2014Inventor: Patrick Franke
-
Patent number: 8765674Abstract: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.Type: GrantFiled: February 24, 2012Date of Patent: July 1, 2014Assignee: NPS Pharmaceuticals, Inc.Inventors: John Dietrich, Sverker Ljunghall, Sven Sjogren
-
Patent number: 8759328Abstract: An oral dosage form comprising a single dose of 25-hydroxy-vitamin D3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days and a pharmaceutically suitable oral carrier system, wherein subsequent single doses at least every 7 days are sufficient to sustain the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml at steady-state pharmacokinetics is disclosed.Type: GrantFiled: July 24, 2009Date of Patent: June 24, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. Deluca, Lori A. Plum, Margaret Clagett-Dame
-
Publication number: 20140170110Abstract: Compounds having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).Type: ApplicationFiled: May 21, 2012Publication date: June 19, 2014Applicant: ALMIRALL, S.A.Inventors: Paul Robert Eastwood, Jacob Gonzalez Rodriguez, Elena Gomez Castillo, Jordi Bach Taña
-
Patent number: 8754067Abstract: This invention discloses 22-haloacetoxy-homopregnacalciferol analogs and specifically 22-bromoacetoxy-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits relatively little calcemic activity and does not promote cellular differentiation off HL-60 leukemia cells, but rather kills the cells. This cell death activity is found in small cell lung carcinoma also, but not in prostate cancer cells. This compound thus causes specific cell death in the absence of changes in calcium levels and without general toxicity in an animal. Therefore it might serve as a useful therapy for treatment of some forms of cancer, such as leukemia and lung cancer.Type: GrantFiled: November 11, 2011Date of Patent: June 17, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal Barycki, Lori A. Plum
-
Patent number: 8748414Abstract: The present invention relates to a complex made up of at least one molecule of statin or a derivative thereof, covalently bonded to at least one hydrocarbon radical including at least 18 carbon atoms and containing at least one 2-methyl-buta-2-ene unit, to nanoparticles of such a complex, and to a method for preparing same, said complex and/or said nanoparticles optionally being in the form of a lyophilizate. The present invention also relates to a pharmaceutical composition including at least one complex and/or nanoparticles such as previously defined. The invention finally relates to said complex and/or to said nanoparticles for the treatment and/or prevention of hyperlipemia and hypercholesterolemia.Type: GrantFiled: October 28, 2009Date of Patent: June 10, 2014Inventors: Patrick Couvreur, Didier Desmaele, Fat'ma Zouhiri, Reddy Harivardhan Lakkireddy
-
Publication number: 20140155358Abstract: The invention relates to compounds which are active as drugs for stimulating the innate antimicrobial peptide system and can be used as antimicrobial drugs. Preferred targets are infections selected from infection of the lung, trachea, urinary tract or kidney, upper GI tract and\or blood. Preferred target pathogens are selected from: Mycobacterium tuberculosis; Pseudomonas bacteria; Haemophilus influenzae; Moraxella catarrhalis. “Preferred” compounds of the invention are. Preferred compounds include 4-phenylbutyric acid or a salt of 4-phenylbutyrate, such as sodium 4-phenylbutyrate, Butyric acid or a salt of butyrate, such as sodium butyrate, or gyceryl tributyrate.Type: ApplicationFiled: April 11, 2012Publication date: June 5, 2014Applicant: AKTHELIA PHARMACEUTICALSInventors: Rubhana Raqib, Birgitta Agerberth, Gudmundur Hrafn Gudmundsson, Roger Stromberg
-
Publication number: 20140154332Abstract: The present invention provides methods of producing dosage forms for formulas of elemental compositions encompassing acetate salts of calcium, magnesium and zinc along with vitamin D3. The acetate salts could be extracted from natural sources such as pearls, coral, and oyster or compounded using synthetic materials. The dosage and ratio of calcium to magnesium was estimated using in vitro and in vivo estimations. The dosage for promoting bone health and alleviation of osteoporosis is about a quarter to a third of the conventional dose.Type: ApplicationFiled: July 27, 2012Publication date: June 5, 2014Applicant: SINOVEDA CANADA, INC.Inventor: Yun Kau Tam
-
Publication number: 20140155360Abstract: A calcium formate composition for oral administration to an individual for the purpose of supplementary dietary calcium is disclosed.Type: ApplicationFiled: February 4, 2014Publication date: June 5, 2014Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventor: Hector F. DeLuca
-
Publication number: 20140155359Abstract: A clear and nutritive microemulsion comprising an aqueous phase in which at least one liposoluble active ingredient is dispersed, a first surfactant included in the group consisting of non-ionic surfactants with a high HLB and non-ionic surfactants with medium HLBs; and a second surfactant, characterized in that said second surfactant is chosen from the group consisting of anionic surfactants which have an HLB ?25.Type: ApplicationFiled: July 13, 2012Publication date: June 5, 2014Applicant: PRAYONInventors: Guy Broze, Claire Pucci, Adeline Navarro
-
Patent number: 8741878Abstract: Novel compositions in petroleum jelly-free unguent form, in particular for topical application, contain a vitamin D compound and optionally an active agent of the family of steroidal anti-inflammatory agents.Type: GrantFiled: May 29, 2009Date of Patent: June 3, 2014Assignee: Galderma S.A.Inventors: Nathalie Willcox, Nathalie Barthez, Karine Nadau-Fourcade, Claire Mallard
-
Patent number: 8741879Abstract: Novel compositions in petroleum jelly-free unguent form, in particular for topical application, contain a vitamin D compound and optionally an active agent of the family of steroidal anti-inflammatory agents.Type: GrantFiled: September 14, 2012Date of Patent: June 3, 2014Assignee: Galderma S.A.Inventors: Nathalie Willcox, Nathalie Barthez, Karine Nadau-Fourcade, Claire Mallard
-
Patent number: 8729054Abstract: This invention discloses 3-desoxy-2-methylene-vitamin D analogs, and specifically (20S)-3-desoxy-1?,25-dihydroxy-2-methylene-vitamin D3 and (20R)-3-desoxy-1?,25-dihydroxy-2-methylene-vitamin D3 as well as pharmaceutical uses therefor. These compounds exhibit relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to monocytes thus evidencing use as anti-cancer agents especially for the treatment or prevention of osteosarcoma, leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. These compounds also exhibit relatively high calcemic activity evidencing use in the treatment of bone diseases.Type: GrantFiled: October 3, 2012Date of Patent: May 20, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Lori A. Plum, Rafal R. Sicinski, Izabela Sibilska
-
Patent number: 8728535Abstract: In one embodiment of the present invention, a pharmaceutically-acceptable single-dosage formulation consists essentially of about 500 mg of vitamin C; about 400 IUs of vitamin D3; about 125 IUs of vitamin E; about 25 mg of vitamin B1; about 3.4 mg of vitamin B2; about 35 mg of niacin; about 35 mg of vitamin B6; about 1.25 mg of folic acid; about 70 mcg of vitamin B12; about 5 mg of pantothenic acid; about 75 mcg of biotin; about 35 mg of magnesium; about 35 mg of zinc; about 1 mg of copper; about 125 mcg of selenium; about 150 mcg of chromium; about 10 mg of alpha lipoic acid; about 35 mg of co-enzyme Q-10; about 400 mcg of lutein; about 125 mcg of lycopene; and at least one or more excipients.Type: GrantFiled: June 19, 2012Date of Patent: May 20, 2014Assignee: Vertical Pharmaceuticals, LLCInventors: Steven A. Squashic, Kevin M. Hudy, David C. Purdy
-
Publication number: 20140134119Abstract: Described herein are novel methods for the treatment of rosacea which include the step of applying of a composition containing a polymetal complex to an area of the skin afflicted with rosacea and novel regimens using such compounds.Type: ApplicationFiled: September 13, 2013Publication date: May 15, 2014Inventors: Joseph R. Faryniarz, Jose E. Ramirez, Hovig Ounanian
-
Publication number: 20140121156Abstract: Nutritional products, compositions, pharmaceutical preparations and methods of use are disclosed for the prevention, suppression and treatment of anemia and/or diabetes and its various associated comorbidities. Uses of Ergothioneine to neutralize free radicals and/or cytokines, reduce oxidative stress, prevent inflammation, stimulate red blood cell production with increased levels of hemoglobin, and/or stabilize iron in its normal 2+ charge for proper oxygen binding and carrying are further disclosed. The extraction of Ergothioneine from whole food sources and bacterium for use in nutritional products, compositions, pharmaceutical preparations and treatments is also disclosed.Type: ApplicationFiled: June 13, 2012Publication date: May 1, 2014Applicant: Entia Biosciences, Inc.Inventor: Marvin S. Hausman
-
Publication number: 20140120060Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating rheumatoid arthritis or asthma.Type: ApplicationFiled: March 15, 2013Publication date: May 1, 2014Applicant: INFINITY PHARMACEUTICALS, INC.Inventors: Vito J. Palombella, Jeffrey L. Kutok
-
Patent number: 8710034Abstract: The invention relates to a method for improving skin lipid barrier function by applying to the skin a composition comprising effective amounts of a protease inhibitor and a cell differentiation enhancer. The composition is useful in promoting skin lipid barrier repair and maintaining the integrity of the lipid barrier. In this regard, the compositions can be used in the treatment and prevention of dry skin, and associated chrono/proto-aging conditions, in the treatment and prevention of irritation on the skin, in the treatment and prevention of UV-related damage to the skin, and in the enhancement of the retention of self-tanning.Type: GrantFiled: April 6, 2012Date of Patent: April 29, 2014Assignee: Color Access, Inc.Inventors: Daniel H. Maes, Jon Anderson, Kenneth D. Marenus, Thomas Mammone, Christina G. Fthenakis
-
Publication number: 20140113012Abstract: The present invention provides compounds and compositions for the amelioration of arthritis and joint injuries by inducing mesenchymal stem cells into chondrocytes.Type: ApplicationFiled: March 26, 2012Publication date: April 24, 2014Applicant: THE SCRIPPS RESEARCH INSTITUTEInventors: Peter Schultz, Laure Bouchez
-
Publication number: 20140112945Abstract: The compounds of formula (1) in which R1, R7, R8, R9, R10, R17, R18, R19, R20 and m have the meanings as given in the description, are novel effective inhibitors of type 4 and type 5 phosphodiesterase.Type: ApplicationFiled: June 12, 2012Publication date: April 24, 2014Applicant: TAKEDA GmbHInventors: Thomas Stengel, Thomas Maier, Alexander Mann, Josef Stadlwieser, Dieter Flockerzi, Andreas Pahl, Ewald Benediktus, Manuela Hessmann, Tobias Kanacher, Ragna Hussong, Christof Zitt, Hans Christof Holst, Rolf-Peter Hummel, Martin Viertelhaus, Hermann Tenor, Torsten Dunkern, Armin Hatzelmann, Christian Hesslinger
-
Publication number: 20140113886Abstract: A stabilized 1,25-dihydroxyvitamin D2 composition which is particularly well suited for pharmaceutical formulations, pharmaceutical formulations of the 1,25-dihydroxyvitamin D2 composition, and a method of making the purified composition by purifying a crude 1,25-dihydroxyvitamin D2 from acetone/water, are disclosed.Type: ApplicationFiled: January 2, 2014Publication date: April 24, 2014Applicant: CYTOCHROMA INC.Inventor: Uttam Saha
-
Publication number: 20140113885Abstract: Described herein are assays directed to determining the level of bioavailable or free vitamin D in a blood sample in a subject. The values determined for bioavailable or free vitamin D indicate whether the subject suffers from insufficient levels of vitamin D. Also described herein are methods of treatment for vitamin D insufficiency.Type: ApplicationFiled: January 6, 2012Publication date: April 24, 2014Inventors: Ravi Thadhani, S. Ananth Karumanchi, Anders Hayden Berg, Ishir Bhan
-
Patent number: 8703195Abstract: Disclosed is a method in which poloxamer, a resin, and/or a tocopherol is/are fused, and the material that is to be treated is intimately dispersed with said melt. After being introduced into the melt, the material that is to be treated is coated with water to prevent hardening, and the spontaneously forming gel is homogenized. The obtained product is composed of a transparent gel that is based on at least one poloxamer, a resin or a tocopherol, and an active substance which is solubilized, dispersed, and stabilized therein and whose consistency ranges from solid, semisolid, i.e. aspic-like, to liquid. The micelles of said solubilized matter remain stable even when the same is diluted well below the CMC of poloxamer.Type: GrantFiled: March 9, 2007Date of Patent: April 22, 2014Assignee: Biorem AGInventor: Hanspeter Strobel
-
Patent number: 8703187Abstract: New dosage forms of vitamin D and calcium carbonate having improved content uniformity are described. The improvements are realized through modifications to the formulation, the raw material specifications, and the process of manufacture.Type: GrantFiled: April 24, 2008Date of Patent: April 22, 2014Assignee: Warner Chilcott Company, LLCInventors: Gregory Paul Dittmar, Andrew Irvine Sokolik
-
Patent number: 8703174Abstract: A pet supplement includes a joint preserving and joint rebuilding composition comprising chicken collagen type II, glucosamine hydrochloride and chondroitin sulfate, a vitamin composition comprising vitamins C, D and K, a mineral composition comprising calcium, magnesium, zinc, copper, manganese and boron, a herbal anti-oxidant cofactor blend comprising citrus bioflavonoids, red grapes anthocyanins, turmeric rhizome, boswellia resin and fennel seed. Each of these ingredients is intimately mixed into the pet supplement and orally delivered to the pet in the form of a segment, paste or powder having a size and weight or other dosage measuring feature adjusted in accordance with the pet's weight. A synergistic action between these ingredients preserves and rebuilds the pet's joints, and is nutritionally beneficial for the pet.Type: GrantFiled: September 15, 2006Date of Patent: April 22, 2014Assignee: I did It IncInventor: Marni Markell Hurwitz
-
Publication number: 20140105884Abstract: Disclosed herein are materials, means and methods for sustained release of therapeutic agents for topical treatments. In particular, disclosed are means and methods for topical treatment of diseases of internal body cavities by embedding therapeutic agents in a slowly degrading biocompatible mixture applied to affected tissue.Type: ApplicationFiled: October 15, 2013Publication date: April 17, 2014Applicant: THERACOAT LTD.Inventors: Marina Konorty, Gil Hakim
-
Publication number: 20140100203Abstract: An oral dosage form comprising a single dose of 25-hydroxy-vitamin D3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days and a pharmaceutically suitable oral carrier system, wherein subsequent single doses at least every 7 days are sufficient to sustain the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml at steady-state pharmacokinetics is disclosed.Type: ApplicationFiled: March 11, 2013Publication date: April 10, 2014Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame
-
Patent number: 8691299Abstract: Disclosed is an ingestible insect repellent composition and method utilizing a mixture of vitamins and extracts of lemon, coffee and/or peppermint as active insect deterrent. The composition may be diluted for easier intake into water, juices, milk, soda, mixed drinks and other beverages. Exemplary embodiments disclosed herein may include creating a premix capable of providing up to 100% of the suggested daily intake of specific Vitamin when diluted in any appropriate beverage. Exemplary embodiments may be utilized to repel insects for hours after ingestion in both humans and animals. The exemplary embodiments may provide this repellant without the harmful effects of other chemicals and repellants.Type: GrantFiled: April 4, 2011Date of Patent: April 8, 2014Inventors: Deveral Bodden, Ana Carro
-
Patent number: 8685949Abstract: The present invention relates to the use of 25-hydroxy-vitamin D3 to improve the general health status of female animals at least during gestation and/or lactation. The invention also relates to the use of 25-hydroxy-vitamin D3 in animal breeding. More particular, the invention relates to the use of 25-hydroxy-vitamin D3 for improving litter size and vitality of piglets in pig breeding and for providing better body frame and increasing gestation backfat gain, reducing lactation backfat loss and increasing lactation feed intake of sows and gilts.Type: GrantFiled: November 23, 2006Date of Patent: April 1, 2014Assignee: DSM IP Assets B.V.Inventors: Thau Kiong Chung, Francisco Feranil Penalba, Gilbert Weber
-
Publication number: 20140086870Abstract: New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).Type: ApplicationFiled: February 18, 2011Publication date: March 27, 2014Inventors: Jordi Bach Taña, Lluis Miquel Pages Santacana, Joan Taltavull Moll, Paul Robert Eastwood, Jacob Gonzalez Rodrigues, Victor Giulio Matassa
-
Publication number: 20140088049Abstract: An apparatus and method for increasing Vitamin D content in mushrooms is disclosed. A mushroom slurry of comminuted or pulverized mushrooms or mushroom parts and liquid, such as water, is passed under a UV light source and subjected to one or more pulses of UV light. The slurry may be conveyed to the UV light source by a vibrating conveyor. After UV light exposure, the treated slurry may be dried and ground into a powder, or the treated slurry may be filtered and the insoluble portion may be dried and ground into a powder. The irradiated mushroom powder has a mass fraction of Vitamin D2 of at least 2500 IU/gram of powder, and more preferably at least 20,000 IU/gram of powder. Irradiated mushroom powder may be incorporated into consumable food product for humans or animals, and/or may be incorporated into topical preparations for cosmetic use.Type: ApplicationFiled: September 27, 2012Publication date: March 27, 2014Applicant: Oakshire Holdings, Inc.Inventors: William F. Chalupa, Gary M. Schroeder
-
Publication number: 20140079666Abstract: In one aspect, the invention relates to novel, broad-spectrum anti-viral, pyrimidinone compounds, methods of use, compositions and kits useful in treating and/or preventing influenza. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: May 5, 2012Publication date: March 20, 2014Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Thomas R. Webb, Vincent A. Boyd
-
Publication number: 20140079785Abstract: A pharmaceutical composition comprises, as a therapeutically active ingredient, a corticosteroid and/or vitamin D derivative incorporated as a solid solution or dispersion in lipid nanoparticles, said lipid nanoparticles being solid at ambient temperature and comprising a first lipid with a melting point above body temperature, the first lipid being a wax selected from the group consisting of esters of C12-24 alcohols and C12-24 fatty acids, glyceryl mono-, di- or triesters of C12-24 fatty acids, C12-24 fatty alcohols, and cholesterol, optionally a second lipid which is an oil at ambient temperature and miscible with the first lipid, and a pharmaceutically acceptable surfactant.Type: ApplicationFiled: March 23, 2012Publication date: March 20, 2014Applicant: LEO PHARMA A/SInventors: Louise Bastholm Jensen, Karsten Petersson
-
Publication number: 20140072647Abstract: The present invention relates to a method for maintaining normoglycemia in a mammal in need thereof, preferably a critically ill patient suffering from acute stress, and to a method for preventing or limiting renal ischemia-reperfusion (I/R) in a mammal, preferably in a critically ill patient suffering from acute stress.Type: ApplicationFiled: March 6, 2012Publication date: March 13, 2014Inventors: Hendrik Jan Cornelis Meijerink, Lekhram Changoer
-
Publication number: 20140073615Abstract: A lipid layer forming composition for topical treatment of psoriasis comprises volatile silicone oil, polar lipid, C2-C4 aliphatic alcohol, and a pharmacologically effective amount of an agent for the treatment of psoriasis, wherein the silicone oil has a boiling point above 180° C., in particular above 200° C. The composition does not comprise polymer silicone. Also disclosed are corresponding methods of treatment and of manufacture of the composition.Type: ApplicationFiled: April 30, 2012Publication date: March 13, 2014Applicant: LIPIDOR ABInventors: Anders Carlsson, Bengt Herslöf, Jan Holmbäck
-
Patent number: 8664205Abstract: Provided is a lotion that exhibits high percutaneous absorption inherent in maxacalcitol, allows the maxacalcitol to be stable, and exhibits less dripping when it is applied to heads. A basic oil-in-water emulsion lotion containing 22-oxa-1?, 25-dihydroxyvitamin D3, medium-chain triglyceride, a nonionic surfactant, and a water-soluble thickener and a method of treatment of skin disorders using the same.Type: GrantFiled: January 30, 2007Date of Patent: March 4, 2014Assignee: Maruho Co., Ltd.Inventor: Shin-ichi Harada